Proton beam therapy followed by Pembrolizumab for giant ocular surface conjunctival malignant melanoma: Case report. Matsuo T, Yamasaki O, Tanaka T, Katsui K, Waki T. Mol Clin Oncol. 16(1):12, 2022.
Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. Fujisawa Y, Ito T, Kato H, Irie H, Kaji T, Maekawa T, Asai J, Yamamoto Y, Fujimura T, Nakai Y, Yasuda M, Matsuyama K, Muto I, Matsushita S, Uchi H, Nakamura Y, Uehara J, Yoshino K. European Journal of Cancer, 145: 210-220, 2021.
Multifunctionality of CD8+ T cells and PD-L1 expression as a biomarker of anti-PD-1 antibody efficacy in advanced melanoma. Manabe K, Yamasaki O, Nakagawa Y, Miyake T, Udono H, Morizane S. J Dermatol, 48: 1186-1192, 2021.
Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study. Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y. Eur J Cancer. 157: 361-372, 2021.
Melanosis of the nipple and areolaの1例． 内藤聖子，松田真由子，馬屋原孝恒，山﨑 修 森実 真． 皮膚科の臨床 63(11): 1752-1753, 2021.
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y. J Immunother Cancer. 9(11): e003134, 2021.
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. ESMO Open. 6(6): 100325, 2021.
2020
Significance of 5-S-cysteinyldopa as a marker for melanoma. Wakamatsu K, Fukushima S, Minagawa A, Omodaka T, Hida T, Hatta N, Takata M, Uhara H, Okuyama R, Ihn H. Mol Sci, 21(2). pii: E432, 2020.
Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan. Otsuka M, Sugihara S, Mori S, Hamada K, Sasaki Y, Yoshikawa S, Kiyohara Y. J Dermatol, 47(4):356-362, 2020.
Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murata N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. J Dermatol Sci, 94(2):284-289, 2019.
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murao N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Cancer Med. 8(5):2146-2156, 2019.
Japanese real-world study of sequential nivolumab and ipilimumab treatment in melanoma. Tsutsumida A, Fukushima S, Yokota K, Yoshikawa Shusuke, Yamasaki O, Tanemura A, Okuyama R, Uhara H, Muto Y, Miyashita A, Akiyama M, Kaji T, Koga H, Kato J, Katayama T, Itakura E, Yamaszaki N, Kiyohara Y. J Dermatol, 46(11): 947-955, 2019.
Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma. Umemura H, Kaji T, Tachibana K, Morizane S, Yamasaki O. Int J Biol Markers, 34(4): 414-420, 2019.
Lacrimal Sac Malignant Melanoma in 15 Japanese Patients: Case Report and Literature Review. Matsuo T, Tanaka T, Yamasaki O. J Investig Med High Impact Case Rep. 2019 Jan-Dec;7
2018
Speckled lentiginous nevus: understanding the process of development and regression. Iwatsuki K, Hamada T, Yamasaki O, Morizane S, Muto M. Br J Dermatol, 178(6): 1447-1448, 2018.
Severe gastritis after administration of nivolumab and ipilimumab. Nishimura Y, Yasuda M, Ocho K, Iwamuro M, Yamasaki O, Tanaka T, Otsuka F. Case Rep Oncol, 11(2): 549-556, 2018.
Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity. Kaji T, Yamasaki O, Takata M, Otsuka M, Hamada T, Morizane S, Asagoe K, Yanai H, Hirai Y, Umemura H, Iwatsuki K. J Dermatol Sci, 85(1):51-57, 2017.
Usefulness of serum 5-S-cysteinyl-dopa as a marker for predicting prognosis and detecting relapse in patients with advanced malignant melanoma. Umemura H, Yamasaki O, Kaji T, Otsuka M, Asagoe K, Takata M, Iwatsuki K. J Dermatol, 44(4):449-454, 2017.
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase II study for advanced melanoma. Yamazaki N, Kiyohara Y, Uhara H, Iizuka H, Uehara J, Otsuka F, Fujisawa Y, Takenouchi T, Isei T, Iwatsuki K, Uchi H, Ihn H, Minami H, Tahara H. Cancer Sci, 108(5):1022-1031, 2017.
Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Matsuo T, Yamasaki O. Clin Case Rep, 5(5):694-700, 2017.
Possible macrophage activation in melanoma patients receiving combined kinase inhibitor therapy following anti-PD-1 therapy: a cytokine profiling study of two cases. Umemura H, Yamasaki O, Morizane S, Iwatsuki K. Ann Oncol, 28(10): 2624-2625, 2017.
Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute. Otsuka M, Yamasaki O, Kaji T, Iwatsuki K, Asagoe K. J Dermatol, 42: 954-961, 2015.
Assessment of melanoma-initiating cell markers and conventional parameters in sentinel lymph nodes of malignant melanoma. Suzuki N, Tanaka M, Shirafuji Y, Otsuka M, Yamasaki O, Asagoe K, Hatta N, Iwatsuki K. Acta Med Okayama, 69(1): 17-27, 2015.
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. J Immunother. 37(2): 84-92, 2014.
Identifying BRAF and KIT mutations in melanoma. Takata M Expert Rev Dermatol. 8(2): 171-6, 2013.
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R. Br J Cancer. 106: 939-946, 2012.
Applicability of radiocolloids, blue dyes and fluorescent indocyanine green to sentinel node biopsy in melanoma. Uhara H, Yamazaki N, Takata M, Inoue Y, Sakakibara A, Nakamura Y, Suehiro K, Yamamoto A, Kamo R, Mochida K, Takenaka H, Yamashita T, Takenouchi T, Yoshikawa S, Takahashi A, Uehara J, Kawai M, Iwata H, Kadono T, Kai Y, Watanabe S, Murata S, Ikeda T, Fukamizu H, Tanaka T, Hatta N, Saida T. J Dermatol. 39: 336-338, 2012.
HRAS-mutated Spitz Nevus on the Cheek in a Middle-aged Man. Kiyohara T, Takata M, Itoh H, Kawami K, Yasuta M, Hayakawa K, Kumakiri M. Acta Derm Venereol. 92(3): 326-327, 2012.
Malignant melanoma arising from an NRAS-mutated medium-sized congenital melanocytic nevus. Kiyohara T, Takata M, Itoh H, Kawami K, Ido H, Ishida H, Kumakiri M. J Dermatol, 39: 1034-5, 2012.
Genetic/epigenetic biomarkers: Distinction of melanoma from other melanocytic neoplasms. Takata M In: Murph M (ed), Diagnostic and prognostic biomarkers and therapeutic targets in melanoma , pp.69-77, Springer, NY, 2012.
A phase I study of vaccination with NY-ESO-1f peptide mix. Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E. International Journal of Cancer. 129(12): 2836-2846, 2011.
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melan. Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, Murphy R, Hoffman EW, Old LJ, Nakayama E, Iwatsuki K. Cancer Immunol Immunother. 57(10):1429-37, 2008.
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E. Cancer immunity. 7: 9, 2007.
Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinate. Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, Miyata H, Yasuda T, Doki Y, Noguchi Y, Kumon H, Tsuji K, Iwatsuki K, Shiku H, Ritter G, Murphy R, Hoffman E, Old LJ, Monden M, Nakayama E. International Journal of Cancer. 120(10): 2178-2184, 2007.
メラノーマの遺伝子異常と今後の分子標的治療． 高田 実. WHAT’S NEW in 皮膚科学 2014-2015、宮地良樹（編）、pp.132-133、メディカルレビュー社、東京、2014
